APHINITY trial
E261835
UNEXPLORED
The APHINITY trial is a large phase III clinical study that evaluated the addition of pertuzumab (Perjeta) to standard trastuzumab-based adjuvant therapy in patients with HER2-positive early breast cancer.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.